New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
NCT ID NCT02581514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a decision algorithm to help doctors diagnose the cause of eosinophilia (high levels of a type of white blood cell). The algorithm guides which tests to do and in what order. Researchers enrolled 53 patients and measured how many followed the algorithm correctly, how often a diagnosis was made, and how long it took. The goal is to make diagnosis faster and more efficient.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the algorithm works well, it could help doctors diagnose the cause of high eosinophil levels more quickly and with fewer tests.
- What could go wrong
- This is a small, completed study (53 people) testing a diagnostic process, not a treatment. The algorithm may not work for everyone or in other hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 53 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2015
- Finished
-
May 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient having one of the three following criteria: * hypereosinophilia\> 1500 / mm3, checked on at least two samples (interval between 2 samples at the discretion of the clinician) * or hypereosinophilia\> 500 cells / mm3 and organ damage with infiltration NCB proven by pathological examination, * or hypereosinophilia\> 500 cells / mm3 and found consistently for at least six months (present on all controls carried out before inclusion). 2. Patient affiliated or beneficiary of a social security system 3. Patient who signed the informed consent Exclusion Criteria: 1. Patient with solid tumors known (under chemotherapy or planned) 2. Patient unable to understand or to adhere to the Protocol 3. Patient unable to give consent 4. Pregnant or breastfeeding women 5. Patient already participating in an interventional trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypereosinophilic syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Médecine Interne A
Limoges, 87000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists launch national effort to unravel mysteries of rare blood disorder
- Drug dasatinib tested for rare blood cancers
- New clues to spot a rare blood disorder
- New hope for rare blood disorder: drug targets overactive immune cells
- New drug aims to tame rare blood disorder flares
- New hope for kids with rare blood disorder: drug may cut flares and steroid use